TAE226 inhibits human neuroblastoma cell survival

Cancer Invest. 2008 Mar;26(2):145-51. doi: 10.1080/07357900701577475.

Abstract

Purpose: Neuroblastoma is one of the most devastating pediatric solid tumors and is unresponsive to many interventions. TAE226 is a novel small molecule FAK inhibitor. We investigated the effects of TAE226 on neuroblastoma cells in vitro.

Materials and methods: Human neuroblastoma cell lines were treated with varying concentrations of TAE226. Following treatment, cell viability, cell cycle, and apoptosis were evaluated.

Results: Treatment of human neuroblastoma cell lines with TAE226 resulted in a concentration dependent decrease in FAK phosphorylation, decrease in cellular viability, cell cycle arrest, and an increase in apoptosis.

Conclusions: Targeting FAK provides potential therapeutic options for the treatment of neuroblastoma and deserves further investigation.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Apoptosis / drug effects*
  • Cell Cycle / drug effects*
  • Cell Proliferation / drug effects*
  • Focal Adhesion Kinase 1 / antagonists & inhibitors*
  • Humans
  • Morpholines / pharmacology*
  • Neuroblastoma / drug therapy*
  • Neuroblastoma / metabolism
  • Phosphorylation / drug effects
  • Tumor Cells, Cultured / drug effects

Substances

  • Morpholines
  • TAE226
  • Focal Adhesion Kinase 1